Rimantadine
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Rimantadine, also known as Flumadine"/> | + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Rimantadine/Rimantainde/1" align="right" caption="Rimantadine, also known as Flumadine"/> |
===Better Known as: Flumadine=== | ===Better Known as: Flumadine=== | ||
* Marketed By: Forest Labs<br /> | * Marketed By: Forest Labs<br /> |
Revision as of 13:07, 6 December 2010
|
Better Known as: Flumadine
- Marketed By: Forest Labs
- Major Indication: Influenza Infection
- Drug Class: M2 Proton Channel Inhibitor
- Date of FDA Approval (Patent Expiration): 1993 (2001)
- 1994 Sales: N/A
- Importance: One of the the first treatments for Influenza Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
M2 Proton Channel Inhibitor Pharmacokinetics[1][2] | ||||||
---|---|---|---|---|---|---|
Parameter | Rimantadine | Amantadine | ||||
Tmax (hr) | 4.3 | 2.5 | ||||
Cmax (ng/ml) | 310 | 402 | ||||
Bioavailability (%) | >90 | >90 | ||||
Protein Binding (%) | 40 | 67 | ||||
T1/2 (hr) | 27.7 | ~15 | ||||
AUC (ng/ml/hr) | 11917 | 5420 | ||||
Dosage (mg) | 100 | 100 | ||||
Metabolism | Negligible | Negligible |
References
- ↑ Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987 Jul;31(7):1140-2. PMID:3662473
- ↑ Wang P, Liang YZ, Chen BM, Zhou N, Yi LZ, Yu Y, Yi ZB. Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. J Pharm Biomed Anal. 2007 Mar 12;43(4):1519-25. Epub 2006 Dec 6. PMID:17156962 doi:10.1016/j.jpba.2006.10.044